Exozymes FY26 Q2 net loss widens 22% to $2.88 million; revenue remains no revenue

• Exozymes posted a net loss of USD 5.25 million for the six months ended June 30, 2026, widening 24.5% year over year.
• Operating loss widened 18.7% to USD 5.34 million, as operating costs rose 18.7% to USD 5.34 million.
• Research and development costs jumped 85.7% to USD 2.56 million, due to higher compensation and lab expenses plus reduced grant funding.
• Cash and cash equivalents climbed 86% to USD 5.65 million following June 2026 offerings with net proceeds of USD 5.86 million.
• Management flagged substantial doubt about going concern, citing working capital of USD 4.55 million as insufficient for 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037725), on August 13, 2026, and is solely responsible for the information contained therein.